Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

DeFronzo, Ralph A., Tripathy, Devjit, Schwenke, Dawn C., Banerji, MaryAnn, Bray, George A., Buchanan, Thomas A., Clement, Stephen C., Henry, Robert R., Hodis, Howard N., Kitabchi, Abbas E., Mack, Wendy J., Mudaliar, Sunder, Ratner, Robert E., Williams, Ken, Stentz, Frankie B., Musi, Nicolas, Reaven, Peter D.·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1010949

Cited by (750)

Items 401–500 of 750

  1. Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
    Muhammad Imtiaz Ahmad, Michael David Shapiro · 2021 · Current Atherosclerosis Reports
  2. Brief lifestyle interventions for prediabetes in primary care: a service evaluation
    Rhys Thatcher, Nicholas Gregory, WY Cheung · 2022 · BMC Family Practice
  3. Intervention for Prevention of Type 2 Diabetes Mellitus Among Prediabetes: A Review of the Literature
    Sopida Thipsawat · 2023 · SAGE Open Nursing
  4. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes
    Manel Mata‐Cases, Sara Artola, Javier Escalada, Patxi Ezkurra Loiola, J.C. Ferrer-García, José Antonio Fornos, Juan Girbés, Itxaso Rica · 2015 · Medicina de Familia SEMERGEN
  5. Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention
    Revathi Balakrishnan, Jeffrey S. Berger, Lisa Tully, Anish K. Vani, Binita Shah, Joseph Burdowski, Edward A A Fisher, Arthur Z. Schwartzbard, Steven P. Sedlis, HOWARD S. WEINTRAUB et al. · 2015 · Diabetes/Metabolism Research and Reviews
  6. Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences
    Gianfranco Di Giuseppe, Gea Ciccarelli, CHIARA MARIA ASSUNTA CEFALO, Francesca Cinti, Simona Moffa, Flavia Impronta, Umberto Capece, Alfredo Pontecorvi, Andrea Giaccari, Teresa Mezza · 2021 · Minerva Endocrinology
  7. Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study
    John Mongan, Hanna Z. Mieszczanska, Brian H. Smith, Susan P. Messing, Richard P. Phipps, Charles W. Francis · 2012 · Thrombosis Research
  8. II Consenso de la Sociedad Chilena de Endocrinología y Diabetes sobre resistencia a la insulina
    Felipe Pollak C., Verónica Araya, Alejandra Lanas, JORGE SAPUNAR, Marco A. Arrese, Carmen Gloria Aylwin, Carmen Gloria Bezanilla, Elena Carrasco, Fernando Carrasco N, Ethel Codner D et al. · 2015 · Revista médica de Chile
  9. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats
    Bethany P. Cummings, Ahmed Bettaieb, James Lawrence Graham, Kimber L. Stanhope, Fawaz G. Haj, Peter Joseph Havel · 2014 · Journal of Endocrinology
  10. Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology
    Luca Sgarra, Francesco Addabbo, Maria Assunta Potenza, Monica Montagnani · 2012 · American Journal of Physiology-Endocrinology and Metabolism
  11. Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective
    Yoshifumi Saisho · 2014 · Journal of Molecular and Genetic Medicine
  12. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance
    Espinoza, Sara E., Wang, Chen-pin, Tripathy, Devjit, Clement, Stephen C., Schwenke, Dawn C., Banerji, Mary Ann, Bray, George A., Buchanan, Thomas A., Henry, Robert R., Kitabchi, Abbas E. et al. · 2016 · AGE
  13. Pathogenesis of Type 2 Diabetes Mellitus
    Ralph Anthony DeFronzo · 2018 · Endocrinology
  14. Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW
    Devjit Tripathy, Stephen C. Clement, Dawn C. Schwenke, MaryAnn Banerji, George A. Bray, Thomas A. Buchanan, Amalia Gastaldelli, Robert R. Henry, Abbas E. Kitabchi, Sunder Raj D. Mudaliar et al. · 2014 · Diabetes Care
  15. Pathogenesis of type 2 diabetes mellitus
    Ralph A. DeFronzo · 2015 · Wiley eBooks
  16. Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?
    Eliot A. Brinton · 2021 · Arteriosclerosis Thrombosis and Vascular Biology
  17. Encapsulation of Pioglitazone into Polymer–Nanoparticles for Potential Treatment of Atherosclerotic Diseases
    Jonas Groner, Martina Tognazzi, Melanie Walter, Daniel Fleischmann, Raphael Mietzner, Christian E. Ziegler, Achim M. Göpferich, Miriam Breunig · 2023 · ACS Applied Bio Materials
  18. Bavachinin selectively modulates PPAR γ and maintains bone homeostasis in Type 2 Diabetes
    Jingwen Liu, Xiaoye Li, Hong Wang, Yan Ren, Yiming Li, Fujiang Guo · 2023 · Phytotherapy Research
  19. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
    Paolo Raggi, Jovana Milić, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi · 2024 · Atherosclerosis
  20. Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes
    Joon Ho Moon, Hun Jee Choe, Soo Kyung Lim · 2024 · Journal of Diabetes Investigation
  21. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
    Muhammad A. Abdul-Ghani, Osama Migahid, Ayman Megahed, Ralph A. DeFronzo, Mahmoud Ali Zirie, Amin Jayyousi · 2017 · The Journal of Clinical Endocrinology & Metabolism
  22. Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension
    Micha J. Rapoport, Angela Chetrit, Dror Cantrell, Ilya Novikov, Jesse Roth, Rachel S. Dankner · 2021 · BMJ Open Diabetes Research & Care
  23. Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition
    Ekaterina S. Kharechkina, Anna B. Nikiforova, Konstantin N. Belosludtsev, Tatyana I. Rokitskaya, Yuri N. Antonenko, Alexey G. Kruglov · 2021 · Pharmaceuticals
  24. Weight Reduction in Diabetes
    Stanley S. Schwartz, Anthony N. Fabricatore, Andrea Diamond · 2012 · Advances in experimental medicine and biology
  25. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes
    Luo, Yingying, Paul, Sanjoy K., Zhou, Xianghai, Chang, Cuiqing, Chen, Wei, Guo, Xiaohui, Yang, Jinkui, Ji, Linong, Wang, Hongyuan · 2017 · Journal of Diabetes Research
  26. Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics
    Teresa Vanessa Fiorentino, Elisabetta Pedace, Elena Succurro, Francesco Andreozzi, Maria Perticone, Angela Sciacqua, Francesco Perticone, Giorgio Sesti · 2019 · The Journal of Clinical Endocrinology & Metabolism
  27. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes
    William C. Knowler, Jill P. Crandall · 2019 · Current Diabetes Reports
  28. Short-term effects of lifestyle intervention in the reversion to normoglycemia in people with prediabetes
    Yuxiang Liu, Haijian Guo, Qing Wang, Jianshuang Chen, Yan Xuan, Jinshui Xu, Yu Liu, Kaicheng Sun, Qian Gao, Zilin Sun et al. · 2021 · Primary care diabetes
  29. Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial
    The TODAY Study Group · 2020 · Diabetes Care
  30. Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects
    Hussein Zaitoon, Muhammad A Abdul‐Ghani, Ralph A. DeFronzo · 2026 · Nature Reviews Nephrology
  31. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial
    for the ACCORD Group of Investigators, Zubin Punthakee, Michael E. Miller, Debra L. Simmons, Matthew C. Riddle, Faramarz Ismail‐Beigi, David J. Brillon, Richard M. Bergenstal, Peter J. Savage, IRENE M. HRAMIAK et al. · 2014 · Diabetologia
  32. Using a Quantitative Measure of Diabetes Risk in Clinical Practice to Target and Maximize Diabetes Prevention Interventions
    Paul A. Rich, Charles F. Shaefer, Christopher G. Parkin, Steven V. Edelman · 2013 · Clinical Diabetes
  33. The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome
    Shuqi Pu, Xiaojie Wu, Xiaoying Yang, Yunzhan Zhang, Yunkai Dai, Yueling Zhang, Xiaoting Wu, Yan Liu, Xiaona Cui, Haiyong Jin et al. · 2018 · Current Drug Metabolism
  34. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case–control study
    Jung-Hee Ha, Dong‐Woo Choi, Keun You Kim, Chung Mo Nam, Eosu Kim · 2021 · Cardiovascular Diabetology
  35. Modulation of cellular energetics by galactose and pioglitazone
    David F. Grimm, Leonardo Altamirano, Sudip Paudel, Leah Welker, Mary E. Konkle, Nilay Chakraborty, Michael A. Menze · 2017 · Cell and Tissue Research
  36. Comparison of the Efficacy of Metformin and Lifestyle Modification for the Primary Prevention of Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Jaahnavi Vajje, Saima Khan, Avneet Kaur, Heemali Kataria, Sahar Sarpoolaki, Aastha Goudel, Ali Hanif Bhatti, Danish Allahwala · 2023 · Cureus
  37. Oral Anti-Diabetic Agents-Review and Updates
    Patience Ogoamaka Osadebe, Estella Odoh, Philip F. Uzor · 2014 · Journal of Advances in Medicine and Medical Research
  38. Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early‐stage type 2 diabetes
    Hidenori Hirukawa, Mitsuru Hashiramoto, Yukio Tanizawa, Kohei Kaku, Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti‐Atherosclerosis in Japan (PREVENT‐J) study group · 2018 · Journal of Diabetes Investigation
  39. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial
    Anupam V. Garrib, Sokoine Lesikari Kivuyo, Katie Bates, Kaushik Laxmidas Ramaiya, Duolao Wang, Edna Majaliwa, Rehema H. Simbauranga, Godbless Charles, Erik van Widenfelt, Huanyan Luo et al. · 2023 · Diabetologia
  40. Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx® Diabetes Risk Score
    Janice A. Kolberg, Robert W. Gerwien, Steven M. Watkins, Linda J. Wuestehube, Mickey S. Urdea · 2011 · Expert Review of Molecular Diagnostics
  41. Insulin sensitivity, and β-cell function in relation to hemoglobin A1C
    Maria Adelaide Marini, Simona Frontoni, Elena Succurro, Franco Arturi, Angela Sciacqua, Marta Letizia Hribal, Francesco Perticone, Giorgio Sesti · 2013 · Nutrition Metabolism and Cardiovascular Diseases
  42. Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
    Mary Angelyn Bethel, Wen Xu, Michael J. Theodorakis · 2014 · Diabetes Obesity and Metabolism
  43. Type 2 Diabetes Treatment in the Patient with Obesity
    Steven K. Malin, Sangeeta Rao Kashyap · 2016 · Endocrinology and Metabolism Clinics of North America
  44. Preventing progression from gestational diabetes mellitus to diabetes: A thought‐filled review
    Michal Kasher Meron, Martin M. Grajower · 2017 · Diabetes/Metabolism Research and Reviews
  45. Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial
    On behalf of the Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators, Atsushi Tanaka, Sho Komukai, Yoshisato Shibata, Hiroyoshi Yokoi, Yoshihiro Iwasaki, Tomohiro Kawasaki, Kenji Horiuchi, Kōichi Nakao, Takafumi Ueno et al. · 2018 · Heart and Vessels
  46. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
    Eddison Godinez Leiva, Fernando Bril · 2020 · Current Hypertension Reviews
  47. Pioglitazone, Bladder Cancer, and the Presumption of Innocence
    Georgios S. Papaetis · 2022 · Current Drug Safety
  48. Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?
    Andrea Palermo, Ernesto Maddaloni, Paolo Pozzilli · 2012 · Expert Opinion on Biological Therapy
  49. Pathogenesis of Type 2 Diabetes Mellitus
    Ralph Anthony DeFronzo · 2018 · Endocrinology
  50. Predicting Type 2 Diabetes Metabolic Phenotypes Using Continuous Glucose Monitoring and a Machine Learning Framework
    Ahmed A. Metwally, Dalia Perelman, Heyjun Park, Yue Wu, Alokkumar Jha, Seth A. Sharp, Alessandra Celli, Ekrem M. Ayhan, Fahim Abbasi, Anna L. Gloyn et al. · 2024 · medRxiv
  51. Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA.ME.LI.A study 7 years follow-up
    B. Monica, Elena Bianco, Lucia Centofanti, Antonio Giampiero Russo, Michele Dei, Paola Zermiani, Camillo Morano, Federica Samartin, Emanuela Bertolini, Francesco Bifari et al. · 2024 · American Journal of Physiology-Endocrinology and Metabolism
  52. Rehabilitation of pioglitazone
    Robert E. J. Ryder, Ralph Anthony DeFronzo · 2015 · The British Journal of Diabetes
  53. Sarcopenia in the setting of nonalcoholic fatty liver
    Marco A. Arrese, Claudio Cabello‐Verrugio, Juan Pablo Arab, Francisco Barrera M., Rene F. Baudrand, Francisco Javier Guarda, Iram Gul, Daniel Cabrera · 2022 · Metabolism and Target Organ Damage
  54. Should Prediabetes be Treated Pharmacologically?
    Mayer B. Davidson · 2023 · Diabetes Therapy
  55. Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
    Laure Sayyed Kassem, Aman Rajpal, Margarita Victoria Ebarle Barreiro, Faramarz Ismail‐Beigi · 2023 · Journal of Diabetes
  56. Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans
    J. Jason Collier, Heidi M. Batdorf, Kaelan L. Merrifield, Thomas M. Martin, Ursula A. White, Éric Ravussin, David H. Burk, Chris R. Cooley, Michael D. Karlstad, Susan J. Burke · 2021 · Biomedicines
  57. A Genome-Wide Association Study of Prediabetes Status Change
    Tingting Liu, Hongjin Li, Yvette P. Conley, Brian A. Primack, Jing Wang, Wen-Juo Lo, Changwei Li · 2022 · Frontiers in Endocrinology
  58. Fraction SX of Maitake Mushroom Favorably Influences Blood Glucose Levels and Blood Pressure in Streptozotocin-Induced Diabetic Rats
    Harry G. Preuss, Bobby W. Echard, Jia Fu · 2012 · Journal of Medicinal Food
  59. Diabetes mellitus: a complete ancient and modern historical perspective
    Chukwuemeka Nwaneri · 2015
  60. Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?
    Leigh Perreault, Kristine Færch, Edward W. Gregg · 2017 · Current Diabetes Reports
  61. Prevention of type 2 diabetes mellitus with acupuncture
    Liwei Shi, Ling Feng, Yanan Yang, Xiaowen Li, Meizhen Zhang, Yueying Zhang, Qing Ni · 2018 · Medicine
  62. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
    Mildred Fátima de la Luz Alvarez-Canales, Sara Stephania Salazar-López, Diana Farfán-Vázquez, Yoscelina Estrella Martínez-López, Jessica Noemí González-Mena, Lilia M. Jiménez-Ceja, Katya Vargas‐Ortiz, María Lola Evia-Viscarra, María Luisa Montes de Oca-Loyola, Franco B. Folli et al. · 2021 · Scientific Reports
  63. Synthesis, antidiabetic activity and molecular docking studies of novel aryl benzylidenethiazolidine-2,4-dione based 1,2,3-triazoles
    Nagesh Patnam, Kishan Chevula, Prasad Chennamsetti, Balaswamy Aleti, Aruna Kumari Kotha, Vijjulatha Manga · 2023 · Molecular Diversity
  64. One‐hour post‐load glucose levels are associated with hepatic steatosis assessed by transient elastography
    Francesco Andreozzi, Elettra Mancuso, Elisa Mazza, Gaia Chiara Mannino, Teresa Vanessa Fiorentino, Franco Arturi, Elena Succurro, Maria Perticone, Angela Sciacqua, Tiziana Montalcini et al. · 2023 · Diabetes Obesity and Metabolism
  65. Electrochemical Assays for the Determination of Antidiabetic Drugs—A Review
    Katarzyna Fendrych, Anna Górska, Joanna Smajdor · 2023 · Micromachines
  66. Perioperative Considerations for Patients on Semaglutide
    Sher‐Lu Pai, Michael A. Smith, William B. Beam, Monica W. Harbell · 2024 · Current anesthesiology reports
  67. Pioglitazone Restores IGFBP-3 Levels Through DNA PK in Retinal Endothelial Cells Cultured in Hyperglycemic Conditions
    S. Thakran, Q. Zhang, Vanessa Marie Morales-Tirado · 2014 · Investigative Ophthalmology & Visual Science
  68. PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling
    Huiying Hua, Julin Yang, Hante Lin, Yang Xi, Manyun Dai, Gang-Ming Xu, Fuyan Wang, Lihong Liu, Tingqi Zhao, Jing Huang et al. · 2018 · Journal of Pharmacy and Pharmacology
  69. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes
    Shumei Miao, Xiao Dong, Xin Zhang, Shenqi Jing, Xiaoliang Zhang, Tingyu Xu, Li Wang, Xianglin L. Du, Hua Xu, Yun Liu · 2018 · Journal of Diabetes
  70. Prediabetes: lifestyle, pharmacotherapy or regulation?
    Jonathan E. Shaw · 2019 · Therapeutic Advances in Endocrinology and Metabolism
  71. Thiazolidinediones (TZDs)
    Jong Chul Won · 2021 · Stroke revisited
  72. Pioglitazone--where do we stand in India?
    Viswanathan Mohan, Sharad Bedi, Ranjit Unnikrishnan I, Binode Kumar Sahay, Shashank Joshpi, Anoop Misra · 2012 · PubMed
  73. Impaired left ventricular diastolic function in T2 DM patients is closely related to glycemic control
    Geoffrey D. Clarke, Marjorie Molina‐Wilkins, Carolina Solis‐Herrera, Verna Méndez, Adriana Monroy, Eugênio Cersósimo, ROBERT J. CHILTON, Muhammad A Abdul‐Ghani, Ralph A. DeFronzo · 2018 · Endocrinology Diabetes & Metabolism
  74. A Second Chance for a PPARγ Targeted Therapy?
    Andrew W. Norris, Curt D. Sigmund · 2012 · Circulation Research
  75. Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches
    Mara Suleiman, Toshiaki Sawatani, Marta Tesi, Xiaoyan Yi, Theodora A. Papadopoulou, Chantal Rufer, Maria Lytrivi, Emanuele Bosi, Frédéric Burdet, Federica Fantuzzi et al. · 2025 · Science Advances
  76. Faith-Based Lifestyle Intervention for Diabetes Prevention Among Adults in Bangladesh
    Bishwajit Bhowmik, Tasnima Siddiquee, Sanjida Binte Munir, Hafiza Nasrin, Tanjimul Islam, Tamanna Afroz, Liya Quamrun Nesa, Shamim Khan, Shamima Akhtar, Farsana Rahman Khan et al. · 2025 · JAMA Network Open
  77. Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes
    DANIEL F. EINHORN, Vivian Andrew Fonseca · 2016 · Endocrine Practice
  78. Evaluation of the value of diabetes risk scores in screening for undiagnosed diabetes and prediabetes: a community-based study in southwestern China
    Shishi Xu, Yuchao Wu, Juan Li, Xiaohui Pan, Xinyue Zhang, Yuqi Liu, Fang Zhang, Nanwei Tong · 2020 · Postgraduate Medicine
  79. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh · 2023 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  80. Treating prediabetes in the obese: are GLP-1 analogues the answer?
    Olivia M. Farr, Christos Socrates Mantzoros · 2017 · The Lancet
  81. Type 2 diabetes: Evolving concepts and treatment
    Eden M Miller, Richard B. Aguilar, Mary E. Herman, Stanley S. Schwartz · 2019 · Cleveland Clinic Journal of Medicine
  82. Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population
    Saadallah Iskandar, Ayman Migahid, Dalia Tarik Kamal, Osama Megahed, Ralph A. DeFronzo, Mahmoud Ali Zirie, Amin Jayyousi, Mahmood Al Jaidah, Muhammad A Abdul‐Ghani · 2019 · BMC Endocrine Disorders
  83. Prevalence of diabetes among patients and the assessment of the awareness of the bidirectional relation between diabetes and periodontal disease
    Reema Lakshmanan, AnishaA Mahtani, Caroline Jacob · 2020 · Journal of Family Medicine and Primary Care
  84. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population
    Sudha S. Shankar, R. Ravi Shankar, Radha A. Railkar · 2015 · Current Therapeutic Research
  85. Management of Prediabetes
    Zachary L. Anderson, Emily M. Scopelliti, Jessica M. Trompeter, Dawn E. Havrda · 2013 · Journal of Pharmacy Practice
  86. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes
    Manel Mata‐Cases, Sara Artola, Javier Escalada, Patxi Ezkurra Loiola, J.C. Ferrer-García, José Antonio Fornos, Juan Girbés, Itxaso Rica · 2015 · Atención Primaria
  87. Non-Alcoholic Fatty Liver Disease in Patients with Diabetes Mellitus: A Clinician’s Perspective
    Sarah M. Kashanian, Michael A. Fuchs · 2015 · International Journal of Digestive Diseases
  88. Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
    Muhammad A Abdul‐Ghani, Amin Jayyous, Nidal Asaad, Sherif Helmy, Jassim M. S. Al Suwaidi · 2018 · Annals of Translational Medicine
  89. Terminal differentiation into adipocyte and growth inhibition by PPARγ activation in human A549 lung adenocarcinoma cells
    Daeyoung Kim, Sun-Ha Moon, Jang-Ho Han · 2020 · Animal Cells and Systems
  90. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
    Stanley S. Schwartz, Barbara E. Corkey, James R. Gavin, Ralph A. DeFronzo, Mary E. Herman · 2024 · BMC Medicine
  91. Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study
    Karol Mateusz Pencina, George Thanassoulis, Michael J. Pencina, Peter Paul Toth, Allan D. Sniderman · 2024 · Cardiovascular Diabetology
  92. A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    Stanley S. Schwartz · 2013 · Current Medical Research and Opinion
  93. Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries
    Samuel E. Dagogo-Jack · 2016 · Springer eBooks
  94. A call to action on prediabetes
    Joy A. Dugan, Alegria Cantillep, Kathryn Newberry, Jay H. Shubrook · 2018 · JAAPA
  95. Pharmacotherapeutic options for prediabetes
    Marc Rendell · 2020 · Expert Opinion on Pharmacotherapy
  96. Prognostic Significance of HbA1c Level in Asian Patients with Prediabetes and Coronary Artery Disease
    Yang Liu, Xunxun Feng, Jiaqi Yang, Tienan Sun, Guangyao Zhai, Qianyun Guo, Yujie Zhou · 2021 · Cardiovascular Innovations and Applications
  97. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi-Kyung Kim, Chang Won Lee et al. · 2022 · Diabetes Obesity and Metabolism
  98. Efficacy and safety of pioglitazone in type 2 diabetes mellitus: a postmarketing observational study.
    Nafrialdi Nafrialdi · 2012 · PubMed
  99. Paradigm Change to Future Health Enhancement through Comprehending the Concept of Obesity Disease in Japan
    Yuka Kohda · 2018 · Journal of Clinical Toxicology
  100. Real-world diabetes prevention: from theory to practice
    Robert E. J. Ryder · 2018 · The Lancet Diabetes & Endocrinology